Abstract
Brain diseases are the most serious health problems; represent a significant and worldwide public health problem. Small interfering RNAs (siRNAs) can initiate specific silencing of genes and are potential therapeutic agents for many genetically influenced diseases including brain disease. However, on systemic administration the blood-brain barrier (BBB) poses most significant obstacle for the therapeutic siRNAs delivery to the brain. Therefore, the development of successful approaches to enhance siRNA delivery to the brain is of immense interest in clinical and pharmaceutical research. At present, intranasal delivery approach serves as an effective mode of direct delivery of siRNAs to brain by bypassing BBB. In this review, we describe the principles of RNA interference (RNAi) machinery; challenges associated with siRNAs in therapeutics brain targeting and summarize the recent progress made in the use of vector based siRNA technology. Further, it is anticipated that intranasal delivery approach will have a very important role to play in the future for the translation of siRNAs therapeutics from bench to bedside for different brain diseases.
Keywords: siRNA, brain diseases, intranasal delivery, brain targeting, nanotechnology, delivery vehicles.
Current Pharmaceutical Design
Title:Brain Targeting of siRNA via Intranasal Pathway
Volume: 21 Issue: 31
Author(s): Chandana Mohanty, Paromita Kundu and Sanjeeb K. Sahoo
Affiliation:
Keywords: siRNA, brain diseases, intranasal delivery, brain targeting, nanotechnology, delivery vehicles.
Abstract: Brain diseases are the most serious health problems; represent a significant and worldwide public health problem. Small interfering RNAs (siRNAs) can initiate specific silencing of genes and are potential therapeutic agents for many genetically influenced diseases including brain disease. However, on systemic administration the blood-brain barrier (BBB) poses most significant obstacle for the therapeutic siRNAs delivery to the brain. Therefore, the development of successful approaches to enhance siRNA delivery to the brain is of immense interest in clinical and pharmaceutical research. At present, intranasal delivery approach serves as an effective mode of direct delivery of siRNAs to brain by bypassing BBB. In this review, we describe the principles of RNA interference (RNAi) machinery; challenges associated with siRNAs in therapeutics brain targeting and summarize the recent progress made in the use of vector based siRNA technology. Further, it is anticipated that intranasal delivery approach will have a very important role to play in the future for the translation of siRNAs therapeutics from bench to bedside for different brain diseases.
Export Options
About this article
Cite this article as:
Mohanty Chandana, Kundu Paromita and Sahoo K. Sanjeeb, Brain Targeting of siRNA via Intranasal Pathway, Current Pharmaceutical Design 2015; 21 (31) . https://dx.doi.org/10.2174/138161282131151013191737
DOI https://dx.doi.org/10.2174/138161282131151013191737 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ACE2/Angiotensin-(1-7)/Mas Receptor Axis in Human Cancer: Potential Role for Pediatric Tumors
Current Drug Targets Neuronal and Vascular Oxidative Stress in Alzheimers Disease
Current Neuropharmacology Recent Developments in the Mechanism of Anticancer Agents Based on Electron Transfer, Reactive Oxygen Species and Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Nature and Nurture in the Early-Life Origins of Metabolic Syndrome
Current Pharmaceutical Biotechnology Intestinal Epithelial Barrier Dysfunction in Disease and Possible Therapeutical Interventions
Current Medicinal Chemistry Transcriptionally Targeted Adenovirus Vectors
Current Gene Therapy Heart Transplantation in Biventricular Congenital Heart Disease: Indications, Techniques, and Outcomes
Current Cardiology Reviews Editorial (Thematic Issue: New Behaviors, New Drugs: The Modern Landscape of Addiction)
Current Pharmaceutical Design New Genetic and Pharmacological Treatments for Cystic Fibrosis
Current Pediatric Reviews The Role of Culture and Ethnicity in the Adjustment to Gynecological Cancer
Current Women`s Health Reviews Cell Clocks and Neuronal Networks: Neuron Ticking and Synchronization in Aging and Aging-Related Neurodegenerative Disease
Current Alzheimer Research Rational Synthesis of Ibandronate and Alendronate
Current Organic Synthesis An Experimental and Theoretical Approach to Understand Fever, DENF & its Cure
Infectious Disorders - Drug Targets Current Concepts for Optimizing the Therapeutic Index of Glucocorticoid Receptor Ligands for Oral and Inhalative Use: Basic Considerations and Clinical Reality
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Ischemic Colitis: Current Diagnosis and Treatment
Current Drug Targets Biocompatible Mater Constructed Microneedle Arrays as a Novel Vaccine Adjuvant- Delivery System for Cutaneous and Mucosal Vaccination
Current Pharmaceutical Design Analysis of NCL Proteins from an Evolutionary Standpoint
Current Genomics Molecular Imaging of σ<sub>1</sub> Receptors In Vivo: Current Status and Perspectives
Current Medicinal Chemistry Peptide Therapeutics in Neurodegenerative Disorders
Current Medicinal Chemistry ADAM10 as a Target for Anti-Cancer Therapy
Current Pharmaceutical Biotechnology